Share This Page
Drug Price Trends for MEROPENEM IV
✉ Email this page to a colleague
Average Pharmacy Cost for MEROPENEM IV
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEROPENEM IV 1 GM VIAL | 00409-1391-22 | 5.70922 | EACH | 2025-03-19 |
| MEROPENEM IV 1 GM VIAL | 00143-9431-10 | 5.70922 | EACH | 2025-03-19 |
| MEROPENEM IV 1 GM VIAL | 00409-3412-10 | 5.70922 | EACH | 2025-03-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Meropenem IV
Overview of Meropenem IV
Meropenem IV is a carbapenem antibiotic used to treat a variety of complicated bacterial infections, including intra-abdominal infections, meningitis, and nosocomial pneumonia. It is administered intravenously and works by interfering with the bacterial cell wall formation, thereby killing the bacteria.
Global Market Size and Growth
The global meropenem API market is projected to experience significant growth over the coming years. According to Cognitive Market Research, the global meropenem API market size is expected to expand at a compound annual growth rate (CAGR) of 4.00% from 2024 to 2031[1].
Regional Market Breakdown
- North America: This region dominated the market in 2024, accounting for around 40% of the global revenue. The demand is driven by the rising rate of healthcare-associated infections (HAIs) and the higher susceptibility of the elderly population to these infections. The market in North America is expected to grow at a CAGR of 2.2% from 2024 to 2031[1].
- Asia Pacific: This region is witnessing a surge in meropenem API demand, driven by the escalation of antibiotic resistance, increased healthcare awareness, and the expansion of generic availability. The Asia Pacific market is expected to grow at a CAGR of 6.0% from 2024 to 2031[1].
- Latin America: The market in Latin America is growing due to the increasing awareness of antimicrobial resistance and the rising use of broad-spectrum antibiotics like meropenem. The CAGR for this region is expected to be around 3.4% from 2024 to 2031[1].
- Middle East and Africa: This region also sees an upswing in meropenem API sales, driven by the need for effective treatments against severe bacterial infections. The CAGR for this region is anticipated to be around 3.7% from 2024 to 2031[1].
Market Drivers
Increasing Prevalence of Antibiotic-Resistant Bacteria
The growing prevalence of antibiotic-resistant bacteria is a significant driver for the meropenem market. Meropenem, being effective against a wide range of bacterial infections, including those resistant to other antibiotics, is in high demand. This trend is expected to continue, fueling the growth of the meropenem market[3].
Hospital Formularies and Generic Availability
Meropenem is often included in hospital formularies, which are lists of approved medications for use within the hospital setting. Additionally, the availability of generic versions of meropenem, particularly in regions like the Asia Pacific, has made the drug more accessible and affordable, contributing to its market growth[1][3].
Price Projections and Cost Analysis
Current Pricing
The cost of meropenem varies based on the dosage and the pharmacy. For example:
- A supply of 10 powder for injection of 500 mg meropenem can cost around $32 to $58.77, depending on the pharmacy[2].
- A 1 gm solution reconstituted of meropenem can cost around $372.20 at full price, but can be reduced to $53.39 with a SingleCare coupon[5].
Future Pricing Trends
Given the increasing demand and the competitive landscape, prices are expected to remain relatively stable but could see slight increases due to production costs and market dynamics.
- Generic Competition: The presence of generic manufacturers like Sandoz and Fresenius Kabi helps keep prices competitive. However, brand-name versions, such as Merrem IV by Pfizer, may maintain higher price points[5].
- Regional Variations: Prices can vary significantly across different regions due to factors such as local healthcare policies, generic availability, and market competition[1][2].
Key Players in the Market
The meropenem market is dominated by several key players, including:
- Menarini Group: Known for their exclusive licensing agreements to develop and market meropenem-based products, such as Vaborem (meropenem and vaborbactam) in China[3].
- Pfizer Inc.: Manufacturer of the brand-name version, Merrem IV[3].
- Sun Pharmaceutical Industries Ltd, Lupin, Kopran Limited, Aurobindo Pharma, and others are also significant players in the carbapenem market[3].
Market Challenges and Opportunities
Challenges
- Antimicrobial Resistance: While meropenem is effective against many resistant bacteria, the ongoing issue of antimicrobial resistance poses a long-term challenge to its efficacy and market sustainability[1][3].
- Regulatory Restrictions: Strict limits on the usage of antibiotic drugs can impact sales and market growth[4].
Opportunities
- Emerging Markets: Regions like the Asia Pacific and Latin America offer significant growth opportunities due to increasing healthcare awareness and the expansion of generic availability[1].
- New Formulations and Combinations: Developments like Vaborem (meropenem and vaborbactam) present opportunities for market expansion and addressing emerging resistance patterns[3].
Key Takeaways
- The global meropenem API market is expected to grow at a CAGR of 4.00% from 2024 to 2031.
- North America and the Asia Pacific are key regions driving the market growth.
- The increasing prevalence of antibiotic-resistant bacteria and the inclusion in hospital formularies are significant market drivers.
- Prices are expected to remain competitive due to generic availability, but regional variations will persist.
- Key players like Menarini Group, Pfizer Inc., and others continue to shape the market through licensing agreements and product developments.
FAQs
What is the primary use of Meropenem IV?
Meropenem IV is used to treat complicated bacterial infections such as intra-abdominal infections, meningitis, and nosocomial pneumonia.
Which regions dominate the meropenem API market?
North America and the Asia Pacific are the dominant regions in the meropenem API market, with North America accounting for around 40% of the global revenue and the Asia Pacific growing at a CAGR of 6.0% from 2024 to 2031[1].
What are the key drivers of the meropenem market?
The key drivers include the increasing prevalence of antibiotic-resistant bacteria, inclusion in hospital formularies, and the expansion of generic availability[1][3].
How much does Meropenem IV typically cost?
The cost of Meropenem IV can vary, but for example, a 1 gm solution reconstituted can cost around $372.20 at full price, or as low as $53.39 with a SingleCare coupon[5].
Who are the major players in the meropenem market?
Major players include Menarini Group, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Lupin, and Aurobindo Pharma, among others[3].
What are the challenges facing the meropenem market?
Challenges include the ongoing issue of antimicrobial resistance and regulatory restrictions on antibiotic usage[1][3][4].
Sources
- Cognitive Market Research: Meropenem API Market Report 2024 (Global Edition)[1].
- Drugs.com: Meropenem Prices, Coupons, Copay Cards & Patient Assistance[2].
- Grand View Research: Carbapenem Market Size & Share Report, 2030[3].
- Research and Markets: Investigation Report on China's Meropenem Market 2021-2025[4].
- SingleCare: Meropenem Coupons & Prices[5].
More… ↓
